1. Introduction {#sec1}
===============

Human bone marrow stromal (also known as skeletal or mesenchymal) stem cells (hBMSC) are increasingly employed in clinical trials for enhancing tissue regeneration following injury \[[@B1]\]. Typically, hBMSC are isolated by their ability to adhere to the plastic surfaces of*in vitro* culture plates. However, the cultured hBMSC exhibit morphological heterogeneity suggesting the presence of functional heterogeneity \[[@B2], [@B3]\]. It has also been suggested that the use of heterogeneous cell populations in clinical trials of hBMSC-based therapies caused variability in the observed treatment effects \[[@B4]\]. Thus, for the efficient use of hBMSC in therapy, better cellular and molecular characterization of hBMSC is required \[[@B1], [@B4]\].

There exist no specific markers that define the hBMSC phenotype. The plastic-adherent hBMSC are defined by the presence of surface expression of some CD surface markers with variable sensitivity and specificity \[[@B1]\]. Single cell clonal analysis revealed that only 25% of the cells are true stem cells based on their ability to differentiate into osteoblasts, adipocytes, and chondrocytes (trilineage differentiation) and to form heterotopic bone and bone marrow organ when implanted*in vivo* subcutaneously in immune deficient mice \[[@B5]\]. The identity of the remaining cells is not clarified, but they may represent lineage-committed cells \[[@B3]\]. Therefore, it is plausible that functional heterogeneity exists in cultured hBMSC, reflecting the*in vivo* functional and developmental heterogeneity of hBMSC \[[@B6]\].

In addition to their ability to differentiate into skeletal tissue cells (known as progenitor function), hBMSC possess immunomodulatory characteristics (known as nonprogenitor functions) \[[@B7]\]. It is not clear whether these different functions are mediated by a number of independent subpopulations within the hBMSC \[[@B2]\]. Only a few studies have tried to identify the subpopulation within cultured hBMSC based on surface markers, for example, STRO1 and alkaline phosphatase (ALP), but limited molecular phenotyping has been conducted \[[@B8]\].

We have previously demonstrated the presence of morphological and functional heterogeneity of clones isolated from telomerized hMSC (hMSC-TERT) cell line \[[@B3]\]. The aim of the present study was therefore to further study in detail the heterogeneity of cultured hBMSC as demonstrated by two clonal cell lines with opposite cellular and functional phenotype. We also employed the DNA microarrays to define their molecular signature and signaling pathways associated with their functional phenotype.

2. Experimental Procedures {#sec2}
==========================

2.1. Cell Culture {#sec2.1}
-----------------

As a model for hBMSC, we employed immortalized hBMSC-TERT cell line that is created from normal human BMSC by overexpression of human telomerase reverse transcriptase gene (hTERT) \[[@B9]\]. The hBMSC-TERT cells have been extensively characterized, and they exhibit similar cellular and molecular phenotype to primary MSC \[[@B10]\]. CL1 and CL2 cells are clonal cell populations of hBMSC-TERT identified in long term culture (passage numbers 15--25) of hBMSC-TERT and were chosen based on their distinct and different morphologies. Cells were cultured in Dulbecco\'s Modified Eagle Medium (DMEM) supplemented with D-glucose 4500 mg/L, 4 mM L-glutamine and 110 mg/L sodium pyruvate, 10% Fetal Bovine Serum (FBS), 1x penicillin-streptomycin (Pen-strep), and nonessential amino acids (all purchased from Gibco-Invitrogen, USA). For some control experiments, primary bone marrow derived MSC (phBMSC) were employed. Sixty milliliters of bone marrow was aspirated from the iliac crest bone of consenting healthy donors. This procedure was approved by the King Khalid University Hospital-King Saud University ethics committee. phBMSC were isolated from bone marrow mononuclear cells by plastic adherence as described previously \[[@B9]\].

2.2. Cell Proliferation {#sec2.2}
-----------------------

Cell proliferation rate was determined by counting cell number and calculating population doubling (PD) rate. The cells were cultured in 25 cm^2^ tissue culture Petri dish at cell density 0.5 × 10^6^ cells (28000 cells/cm^2^). At confluence, the cells were trypsinized and counted manually by hemocytometer. At each passage, population doubling was determined by the following formula: log⁡*N*/log⁡2, where *N* is the number of cells at confluence divided by the initial cell number. Cumulative PD level is the sum of population doublings, and PD rate is PD/time in culture.

2.3. Flow Cytometry {#sec2.3}
-------------------

Cells were trypsinized to a single cell suspension, were recovered by centrifugation at 200 g for 5 min, washed twice in ice-cold PBS supplemented with 2% BSA, and resuspended at a concentration of 10^5^ cells/antibody. After incubation with the preconjugated antibodies, or matched isotype controls, for 30 min on ice in the dark, cells were washed with PBS, resuspended in 500 *μ*L of PBS, and analyzed in the BD FACSCalibur flow cytometer (BD Biosciences). Living cells were gated in a dot plot of forward versus side scatter signals acquired on a linear scale. At least 10,000 gated events were acquired on a log fluorescence scale. Positive staining was distinct as the emission of a fluorescence signal that surpassed levels achieved by \>99% of control cell population stained with corresponding isotype antibodies. The ratios of fluorescence signals versus scatter signals were calculated, and histograms were generated using the software Cell Quest Pro Software Version 3.3 (BD Biosciences). The following antibodies were used all from BD Biosciences: FITC-PE-APC-Mouse IgG1k isotype control, APC-Mouse Anti-Human CD44 (\#559942), FITC-Mouse Anti-Human CD63 (\#557305), PE-Mouse Anti-Human CD73 (\#550257), PE-Mouse Anti-Human CD105 (\#560839), PE-Mouse Anti-Human CD146 (\#550315), PE-Mouse Anti-Human CD166 (\#560903), and Alexa Fluor® 488 Mouse Anti-Human Alkaline Phosphatase (\#561495).

2.4. Electron Microscopy {#sec2.4}
------------------------

After trypsinizing the hBMSC cells from the flasks or 6-well plates were collected, the samples were washed with PBS, and the pellets were resuspended directly in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2), and kept at 4°C for 4 hr. First, the cells were washed with 0.1 M phosphate buffer (pH 7.2) and transferred to 1% osmium tetroxide (OsO4) solution in 0.1 M phosphate buffer (pH 7.2) for two hr. The cells were dehydrated in ascending grades of ethanol. The cells were then resuspended in acetone and were aliquoted into BEEM embedding capsules and infiltrated with acetone: resin mixture followed by embedding in a pure resin mixture for two hr. Semithin sections (0.5 *μ*m thickness) and ultrathin sections (70 nm thickness) were prepared, examined, and photographed under a transmission electron microscope (TEM) (Jeol 1010, Jeol, Tokyo, Japan).

2.5. *In Vitro* Osteoblast Differentiation {#sec2.5}
------------------------------------------

Cells were grown in standard DMEM growth medium in 6-well plates at 20,000 cell/cm^2^. When 70--80% confluence was achieved, test cells were cultured in DMEM supplemented with osteoblastic induction mixture (referred to as OS) containing 10% FBS, 1% Pen-strep, 50 *μ*g/mL L-ascorbic acid (Wako Chemicals, Neuss, Germany), 10 mM *β*-glycerophosphate (Sigma) and 10 nM calcitriol (1*α*,25-dihydroxyvitamin D3; Sigma), and 10 nM dexamethasone (Sigma); noninduced cells (referred to as Cont) were cultured in normal growth media for the same duration as induced. The media were replaced three times per week. Cells cultured in standard culture medium were considered as control. At day 14 of differentiation, mineralized nodules became apparent and were stained with Alizarin Red S and ALP.

2.6. *In Vitro* Adipocyte Differentiation {#sec2.6}
-----------------------------------------

Cells were grown in standard DMEM growth medium in 6-well plates at 0.3 × 10^6^ cells/mL. At 90--100% confluence, cells were cultured in DMEM supplemented with adipogenic (Adip) induction mixture containing 10% FBS, 10% Horse Serum (Sigma), 1% Pen-strep, 100 nM dexamethasone, 0.45 mM isobutyl methylxanthine (Sigma), 3 *μ*g/mL insulin (Sigma), and 1 *μ*M Rosiglitazone (Novo Nordisk, Bagsvaerd, Denmark). The media were replaced three times per week. Cells cultured in standard culture medium were considered as control. From day 3 of differentiation, small lipid droplets became visible and at day 7 they were stained with Oil Red-O and Nile red.

2.7. *In Vitro* Chondrogenic Differentiation {#sec2.7}
--------------------------------------------

Both CL1 and CL2 cells were trypsinized and counted, around 1 × 10^6^ cells taken in each 15 mL conical tube centrifuged at 400 ×g for 5 minutes. For chondrocyte differentiation pellet culture system used, chondrocyte induction was done in media containing advanced DMEM/F12 supplemented with 1% ITS Premix Tissue Culture Supplement, 100 nM dexamethasone, Glutamax, and 10 ng/mL transforming growth factor-beta-3 (TGF*β*-3). Cells were maintained in chondrocyte differentiation media for 21 days and changed every two days.

2.8. Cytochemical Staining {#sec2.8}
--------------------------

### 2.8.1. Alkaline Phosphatase (ALP) Staining {#sec2.8.1}

CL1 and CL2 cells were stained before OS differentiation for the basal ALP expression and after OB differentiation at day 7 of induction. Cells cultured in 6-well plates were washed in PBS −/− (-Ca, -Mg) and fixed in acetone/citrate buffer 10 mM at pH 4.2 for 5 min at room temperature. The Naphthol/Fast Red stain \[0.2 mg/mL Naphthol AS-TR phosphate substrate (Sigma)\] \[0.417 mg/mL of Fast Red (Sigma)\] was added for one hour at room temperature.

Histological tissue blocks were sectioned at 4 microns. Immunohistochemical staining was performed on CL1 and CL2 chondrocyte 3D pellets using DAKO EnVision and PowerVision according to the manufacturer\'s instructions (DAKO, Glostrup, Denmark). Briefly, paraffin sections were incubated for 1 hour at room temperature with primary antibodies diluted in ChemMate (DAKO) (Human Anti-Col-10 and Human Anti-Col-2 ABI). Sections were washed subsequently in Tris-buffered saline (TBS, 0.05 M, pH 7.4), incubated for 30 minutes with secondary anti-mouse Ig/HRP-conjugated polymers (K4001, En Visionþ, DAKO), and visualized with 3,30-diaminobenzidine tetrahydrochloride (DAB, S3000, DAKO) or with 3-amino-9-ethylcarbazole (AEC, DAKO) according to manufacturer\'s instruction. Controls were performed with nonimmune immunoglobulins of the same isotype as the primary antibodies (negative controls) and processed under identical conditions. Alcian blue staining was used to detect chondrocytes. Sections of paraffin-embedded implants were stained with Alcian blue (Sigma) solution, pH 2.5; at this pH all the glycoproteins (neutral and acidic) will be stained blue.

2.9. Alizarin Red S Staining for Mineralized Matrix {#sec2.9}
---------------------------------------------------

Seven-day-old OS differentiated cells in 6-well plates were used for Alizarin Red S staining. The cell layer was washed with PBS and then fixed with 70% ice-cold ethanol for 1 hr at −20°C. After removing the ethanol, the cell layer was rinsed with distilled water and stained with 40 nM AR-S (Sigma) pH 4.2 for 10 minutes at room temperature. Excess dye was washed off with water followed by a wash with PBS for few minutes to minimize nonspecific AR-S stain.

For quantifying the Alizarin Red S staining, the air-dried plates, the Alizarin Red S dye was eluted in 800 *μ*L of acetic acid incubated in each well for 30 minutes at room temperature as described \[[@B11]\] and measured in spectrophotometer (BioTek, Epoch) at 405 nm.

2.10. Quantitative ALP Activity {#sec2.10}
-------------------------------

To quantify ALP activity in CL1 and CL2 hBMSC before and after OS differentiation, we used the BioVision ALP activity colorimetric assay kit (BioVision, Inc, CA, USA) with some modifications. Cells were cultured in 96-well plates under normal conditions; then on day of analysis, wells were rinsed once with PBS and were fixed using 3.7% formaldehyde in 90% ethanol for 30 seconds at room temperature. Subsequently, fixative was removed, and 50 *μ*L of pNPP solution was added to each well and incubated for 1 hour in the dark at room temperature. The reaction was subsequently stopped by adding 20 *μ*L stop solution and gently shaking the plate. OD was then measured at 405 nm.

2.11. Oil Red-O Staining for Lipid Droplets {#sec2.11}
-------------------------------------------

CL1 and CL2 cells differentiated to adipocytes with Adip induction media at day 7 were used. Accumulated cytoplasmic lipid droplets were visualized by staining with Oil Red-O. After washing cells grown in 6-well plates with PBS, the cells were fixed in 4% formaldehyde for 10 min at room temperature and then rinsed once with 3% isopropanol and stained for 1 hr at room temperature with filtered Oil Red-O staining solution (prepared by dissolving 0.5 g Oil Red-O powder in 60% isopropanol). To quantify staining of fat droplets, Oil Red-O was used as a stain. Oil Red-O was eluted by adding 100% isopropanol to each well, and color changes were measured by spectrophotometer at 510 nm (BioTek Spectrophotometer, Epoch).

2.12. Nile Red Fluorescence Determination and Quantification of Adipogenesis {#sec2.12}
----------------------------------------------------------------------------

A stock solution of Nile red (1 mg/mL) in DMSO was prepared and stored at −20°C protected from light. Staining was performed on unfixed cells. Cultured undifferentiated and day 7 adipocyte differentiated cells were grown in Corning polystyrene; flat bottom 96-well TC-treated black microplates (Corning, NY, USA) were washed once with PBS. The dye was then added directly to the cells (5 *μ*g/mL in PBS), and the preparation was incubated for 10 min at room temperature and then washed twice with PBS. Fluorescent signal was measured using SpectraMax/M5 fluorescence spectrophotometer plate reader (Molecular Devices Co, Sunnyvale, CA, USA) using bottom well-scan mode where nine readings were taken per well using Ex (485 nm) and Em (572 nm) spectra.

2.13. Quantitative Real-Time PCR (qRT-PCR) Analysis {#sec2.13}
---------------------------------------------------

Total RNA was extracted using MagNA pure compact RNA isolation kit (Roche Applied Science, Germany, Cat number 04802993001) in an automated MagNA pure compact system (Roche, Germany) as recommended by the manufacturer. The total RNA was quantified by Nanodrop spectrophotometer (Nanodrop 2000, Thermo Scientific, USA). Complementary DNA (cDNA) was synthesized from 1 *μ*g of the RNA samples using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, USA) using Labnet, Multigene thermocycler according to the manufacturer\'s instructions. Relative levels of mRNA were determined from cDNA by real-time PCR (Applied Biosystems-Real-Time PCR Detection System) with Power SYBR Green PCR kit (Applied Biosystems, UK) according to the manufacturer\'s instructions. Following normalization to the reference gene GAPDH, quantification of gene expression was carried out using a comparative Ct method, where ΔCt is the difference between the CT values of the target and the reference gene, and fold induction was performed from the control (Cont) for the same time point. Primers (Supplementary Table  1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/9378081>) were obtained from Applied Biosystems (USA) as TAQMAN primers, or previously published primers were used (see Supplementary Table  1).

2.14. DNA Microarray Global Gene Expression Analysis {#sec2.14}
----------------------------------------------------

Four hundred ng of total RNA was used as input for generating biotin-labeled cRNA (Ambion, Austin, TX, United States). cRNA samples were then hybridized onto Illumina® human-8 BeadChips version 3. Hybridization, washing, Cy3-streptavidin staining, and scanning were performed on the Illumina BeadStation 500 platform (Illumina, San Diego, CA, USA), according to the manufacturer\'s instructions, and everything was done in triplicate. Expression data analysis was carried out using the Partek® genomic suite software. Raw data were background-subtracted, normalized using the "rank invariant" algorithm, and filtered for significant expression on the basis of negative control beads. Genes were considered significantly expressed with detection *p* values ≤ 0.01. Differential expression analysis was performed with the Illumina custom method using freshly isolated primary hBMSC (used at passage 3) as a reference control. The following parameters were set to identify statistical significance: differential *p* values ≤ 0.01; fold change ratio \> 1.5. Pathway analysis was performed using DAVID Bioinformatics Resources 6.7 (<http://david.abcc.ncifcrf.gov/>) and GeneSpring GX software (Agilent Technologies). Pathway analysis for CL1 OS D14 versus CL2 OS D14 was conducted using the Single Experiment Pathway analysis feature in GeneSpring 12.0 (Agilent Technologies).

2.15. Small Interfering (si)RNA Transfection {#sec2.15}
--------------------------------------------

For transfection, hBMSC in logarithmic growth phase were transfected with Silencer Select Predesigned ALP siRNA (25 nM) (Assay ID; s1298 and Cat number 4390824) (Ambion, The RNA Company, USA) using Lipofectamine RNAiMAX Reagent (Invitrogen, CA, USA) plus serum-free Opti-MEM®I medium under the conditions described by the manufacturer. At day 3 of transfection, the cells were induced for osteogenic differentiation for an additional 7 days. ALP staining was used as a control for the siRNA transfection efficiency and timeline.

2.16. Statistical Analysis {#sec2.16}
--------------------------

All of the results were presented as the mean and standard deviation (SD) of at least 3 independent experiments, with 3--5 technical repeats in each experiment. Student\'s *t*-test (two-tailed) was used for testing differences between groups. *p* value \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Comparison between CL1 and CL2: Differences in Morphology, Proliferation, and Marker Expression Profile {#sec3.1}
------------------------------------------------------------------------------------------------------------

We isolated two distinct clonal cell populations of hBMSC-TERT: hBMSC-CL1 and hBMSC-CL2 (for easiness will be termed hereafter CL1 and CL2) based on differences in cell morphology ([Figure 1(a)](#fig1){ref-type="fig"}). CL1 cells had cuboidal morphology whereas CL2 cells have spindle-shaped fibroblast-like morphology. CL1 cells had higher proliferation rate compared to CL2 ([Figure 1(b)](#fig1){ref-type="fig"}): mean PD rates of CL1 and CL2 were 0.714 and 0.429 PD/day, respectively ([Figure 1(b)](#fig1){ref-type="fig"}). Both CL1 and CL2 expressed surface marker profiles characteristics of hBMSC (\>90%): CD44+, CD63+, CD73+, CD105+, and CD166+ ([Figure 1(c)](#fig1){ref-type="fig"}). However CL1 cells showed higher expression of CD146 (92.7% versus 12%) and ALP (98% versus 0%) compared to CL2 ([Figure 1(d)](#fig1){ref-type="fig"}). TEM revealed the presence of abundant pseudopodia in CL1 indicating high motility ([Figure 1(e)](#fig1){ref-type="fig"}(A)) as well as well-developed mitochondria and rough endoplasmic reticulum (rER) suggesting high metabolic activity. CL2 cells contained abundant phagocytic vacuole (pv), microvilli (mi), and lysosomes (ly) ([Figure 1(e)](#fig1){ref-type="fig"}).

We performed quantitative real-time PCR (RT-PCR) for genes expressed in mesodermal progenitor cells \[[@B12]\]. CL1 expressed higher levels of BMP4, MIXL1, WNT3a, and TWIST compared to CL2 ([Figure 1(f)](#fig1){ref-type="fig"}, *p* \< 0.01). In contrast, CL2 expressed higher levels of Kinase Insert Domain Receptor (Type III Receptor Tyrosine Kinase) (KDR) expressed in endothelial cells and smooth muscle myosin heavy chain gene (smMHC) expressed in smooth muscle cells ([Figure 1(f)](#fig1){ref-type="fig"}).

3.2. CL1 Cells Exhibit Enhanced Osteoblast Differentiation {#sec3.2}
----------------------------------------------------------

Following osteoblast (OB) differentiation induction, ALP staining and ALP enzymatic activity were significantly higher in CL1 compared to CL2 cells ([Figure 2(a)](#fig2){ref-type="fig"}, *p* \< 0.01). Similarly, Alizarin Red staining and quantitation of formed mineralized matrix were more pronounced in CL1 cells ([Figure 2(b)](#fig2){ref-type="fig"}, *p* \< 0.01). In addition, CL1 cells expressed higher levels of osteoblastic genes, ALP, RUNX2, and osteopontin (OPN) ([Figure 2(c)](#fig2){ref-type="fig"} upper panel) compared to CL2 cells.

Global gene expression microarray analysis of OB differentiated cells at day 14 showed around 1060 genes significantly upregulated more than 2-fold (*p* \< 0.01) in CL1. Among the upregulated genes, 80 genes were annotated to bone development and osteoblast differentiation ([Table 1](#tab1){ref-type="table"}). The highest upregulated genes included paired-like homeodomain 2 (PITX2), Insulin-like growth factor 1 (IGF1) and collagen, type V, alpha 3 (COL5A3), osteomodulin (OMD), and T-box 15 (TBX15) ([Table 1](#tab1){ref-type="table"}). Furthermore, several known osteoblast-related genes were upregulated in CL1 cells such as bone morphogenetic protein 6 (BMP6), fibroblast growth factor receptor 3 (FGFR3), insulin-like growth factor binding protein 5 (IGFBP5), and vitamin D (1,25-dihydroxyvitamin D3) receptor (VDR) ([Table 1](#tab1){ref-type="table"}). On the other hand, 1200 genes were upregulated in CL2 cells: 255 genes were annotated to immunity and immune response and defense. This category included genes from, complement system, chemokine (C-C motif) ligands, interferon family, chemokine (C-X-C motif) ligands, and receptor, major histocompatibility complex class II molecules, interleukins, and tumor necrosis factor receptor superfamily ([Table 2](#tab2){ref-type="table"} and Supplementary Table 3).

3.3. CL1 Cells Exhibit Enhanced Adipocyte Differentiation {#sec3.3}
---------------------------------------------------------

We observed significant differences between CL1 and CL2 in their response to adipocytic differentiation induction. CL1 differentiated readily to adipocytes compared to CL2 ([Figure 2(d)](#fig2){ref-type="fig"}, lower panel) evidenced by higher levels of adipocytic markers gene expression, LPL (lipoprotein lipase), and adiponectin, as well as formation of mature lipid filled adipocytes visualized by Oil Red-O staining and quantitative Nile red staining ([Figure 2(d)](#fig2){ref-type="fig"}).

3.4. CL1 Cells Differentiate to Chondrocytic Lineage {#sec3.4}
----------------------------------------------------

In pellet cultures, CL1 cells formed 3D pellets containing proteoglycan-secreting chondrocytes, which stained positive with Alcian blue. Limited chondrocyte differentiation was visible in cell pellets of CL2 cells. The differentiated chondrocytes in CL1 pellets expressed higher levels of collagen X and collagen II, which was overlapping the Alcian blue stain ([Figure 2(e)](#fig2){ref-type="fig"}).

3.5. Molecular Signature of CL1 and CL2 Cells {#sec3.5}
---------------------------------------------

To define the molecular signature and molecular differences between CL1 and CL2, we compared the basal gene expression pattern of CL1 and CL2 cells using DNA microarrays. The PCA analysis showed a clear separation between CL1 and CL2 (Supplementary Figure 1). Comparison between CL1 with CL2 showed that 915 genes were differentially expressed in the two cell lines (\>2-fold, *p* \< 0.01): 462 genes were upregulated, and 452 were downregulated in CL1 versus CL2. The most relevant genes that were upregulated in CL1 are listed in [Table 3(a)](#tab3){ref-type="table"}. Among these 35 highly expressed genes in CL1, the following 11 genes were present in skeletal and muscular system development and function: FOLR3, CCL3L1, SERPINB2, POSTN, IGFBP5, CCL3, NOV, ALP, TNFRSF11B, ACTG2, and CDH11 ([Table 3(a)](#tab3){ref-type="table"}). Functional annotation of the upregulated genes in CL1 using the Ingenuity Pathway Analysis (IPA) revealed enrichment in the following categories: "tissue development," "skeletal and muscular system development and function," and "organismal development" ([Table 3(b)](#tab3){ref-type="table"}). Furthermore, the DAVID annotation tool was employed to assess the functional relationships of the upregulated genes in CL1 showing enrichment in ontologies: "skeletal and muscular system development and function" that included bone size, osteoblast differentiation, bone mineralization, and bone mineral density ([Table 3(c)](#tab3){ref-type="table"}). CL1 exhibited upregulation of WNT pathway ligands: WNT5B (2-fold) and LRP5 (2-fold) ([Table 1](#tab1){ref-type="table"}). Also, ALP was among the highly expressed genes together with POSTN, IGFBP5, SPP1, IL-6, and DKK1 (Tables [3](#tab3){ref-type="table"}(a) and [1](#tab1){ref-type="table"}). These genes are known to play an important role in osteoblast differentiation and bone formation. For CL2, inhibitors of WNT pathway were upregulated and included SFRP1 (11-fold), DKK2 (3.2-fold), FGF2 (3.1-fold), and GBP2 (2.4-fold). Functional annotation of the upregulated genes in CL2 revealed enrichment in the following categories: "developmental process," "multicellular organismal process," "biological adhesion," and "immune system process" (Supplementary Table 2A). In-depth analysis of the biological processes revealed several immune-related pathways: "MAPKKK cascade," "immunity and defense," "signal transduction," "extracellular matrix protein-mediated signaling," and "interferon-mediated immunity," among others that were upregulated (Supplementary Table 2B). Also, 40 genes related to immune system related factors were identified as significantly enriched in CL2 compared to CL1 cells (Supplementary Table 2C). We chose the following genes for validation of the microarray results: NOV, IGFBP5, ALP, TAGLN, and CDH11 as they were highly expressed in CL1. RT-PCR analysis confirmed the microarray results ([Figure 3](#fig3){ref-type="fig"}).

Furthermore, we compared the molecular phenotype of CL1 and CL2 cells with that of phBMSC. We found that more than 80% of the genes expressed in CL1 and 90% in CL2 cells were common with primary phBMSC (Supplementary Figure 2), suggesting that CL1 and CL2 molecular phenotype exist within the heterogeneous population of phBMSC cultures.

3.6. ALP Knockdown Impairs Differentiation of CL1 Cells {#sec3.6}
-------------------------------------------------------

Since ALP has been suggested as a marker for hBMSC progenitor cell lineage commitment \[[@B13]\] and was highly upregulated in CL1 cells, we tested its biological role in CL1 cells. ALP siRNA transfection decreased ALP protein level, ALP activity, and mRNA gene expression compared to control cells transfected with control siRNA (*p* \< 0.01) and this inhibition was detectable up to day 7 days after osteoblast differentiation induction (Figures [4(A)](#fig4){ref-type="fig"} and [4(B)](#fig4){ref-type="fig"}). At day 14 of differentiation, mineralization ability of CL1 was significantly impaired ([Figure 4(C)](#fig4){ref-type="fig"}). In addition, we found that the number of mature adipocyte formations was significantly reduced to more than 75% (*p* \< 0.01) ([Figure 4(D)](#fig4){ref-type="fig"}).

To identify relevant adipocyte differentiation associated genes that were targeted by ALP deficiency, we compared the downregulated genes of ALP deficient CL1 with the upregulated genes identified during adipocytic differentiation of CL1. We identified 62 genes that were common ([Figure 5(a)](#fig5){ref-type="fig"}, [Table 4](#tab4){ref-type="table"}) and among these genes were genes related to metabolism (primarily lipid and carbohydrate) and transport including CYB5B, CHST1, TAP1, ATP8A1, LRP8, PLCD1, and FABP5 ([Table 4](#tab4){ref-type="table"}). We further performed quantitative real-time PCR of ALP deficient CL1 cells during adipocyte differentiation. The following adipocyte-associated genes were downregulated: PPAR*γ*2, LPL, and aP2 ([Figure 5(b)](#fig5){ref-type="fig"}), confirming impairment of adipocytic differentiation of ALP deficient CL1 cells.

4. Discussion {#sec4}
=============

We extensively studied two cell populations within cultured hBMSC that were identified based on differences in morphology. Cellular and molecular studies revealed differences in growth, differentiation capacity, and molecular signature. Our data support the notion of the presence of cellular and functional heterogeneity among cultured hBMSC.

Cellular heterogeneity of cultured hBMSC is recognized in an increasing number of reports. Several extrinsic and intrinsic factors may contribute to the observed hBMSC heterogeneity. Extrinsic factors include donor-to-donor variations in the number and quantity of initiating cells, which result in differences in cell growth rate and differentiation capacity \[[@B14], [@B15]\]. Intrinsic factors have been examined employing single cell clonal analysis and revealed variations in differentiation potential among individual colonies within hBMSC cultures ranging from the presence of cells with trilineage (osteoblast, adipocytes, and chondrocyte) potency to cells with null potency \[[@B16]\]. Also, variations in the ability of clonal cells to form heterotopic bone when implanted*in vivo* have been reported \[[@B5]\]. Our study corroborates these findings and provides more detailed cellular and molecular phenotyping of two examples of cell populations that exist within the heterogeneous hBMSC cultures \[[@B17]\].

Determining the molecular signature of CL1 and CL2 using whole genome microarray analysis showed enrichment of lineage-commitment associated genes in CL1. For example, insulin-like growth factor 5 (IGFBP5) and interleukin 6 (IL6) were 14.7- and 3.3-fold upregulated in CL1 cells, respectively. Both factors are expressed in osteoprogenitor cells and important for osteoblast maturation \[[@B18]\]. We also observed that periostin (POSTN) gene was highly upregulated in CL1 cells (15.6-fold); POSTN is a 90 kDa secreted protein, originally identified in murine osteoblast-like cells and is upregulated by PTH \[[@B19]\]. Several studies employing murine and human cells have revealed important role of POSTN in osteoblast differentiation and during development in intramembranous ossification \[[@B20]--[@B23]\]. Another factor identified in CL1 cells is nephroblastoma overexpression (NOV) which is a member of the Cyr 61, connective tissue growth factor (CNN) family. The CCN family of proteins promotes osteoblast differentiation through interaction with integrins, WNT, BMP, and NOTCH signaling pathways \[[@B24]--[@B26]\]. In addition, a large number of signaling molecules known to be regulators of hBMSC lineage specific differentiation, for example, insulin-like growth factors \[[@B27]--[@B29]\], WNT \[[@B30]--[@B32]\], and MAPK \[[@B33]--[@B35]\], were enriched in CL1 cells. In contrast, CL2 expressed high levels of immune-related genes which may explain the poor differentiation response to osteoblast or adipocyte lineage. In a recent study the authors used telomerized hBMSC and showed clearly a clonal population that had very low*in vitro* and*in vivo* differentiation ability; however they had enhanced immune-related features including high IL7 expression. These nullipotent cells expressed CD317 which was associated with remarkably high basal level expression of factors with a proinflammatory and antiviral function \[[@B17]\]. We observed that this molecular phenotype was associated with distinct ultrastructural characteristics of the cells. In particular, CL2 had abundant phagocytic vacuole, microvilli, and lysosomes, features reminiscent of ultrastructure of immune-regulatory cells. Our data thus support the increasingly recognized feature that hBMSC exhibit immune modulatory functions and a part of the innate immune response \[[@B17]\].

We observed that ALP protein expression and enzymatic activity were significantly different between CL1 and CL2 cell lines and were thus a potential marker that distinguishes different cell populations with progenitor functions (CL1) from cells with nonprogenitor functions (CL2). ALP is expressed in a wide variety of tissues, including kidneys, bone, and liver \[[@B36], [@B37]\], but tissue-nonspecific ALP (ALPL) is considered a commitment marker for osteoblastic lineage \[[@B13], [@B38]\]. However, in a recent study the authors examined the differentiation potential of a number of hMSC clones*in vitro* and*in vivo* and reported that the hMSC clones with high levels of ALP expression were committed to trilineage differentiation \[[@B13]\]. Our data corroborate and extend these findings by reporting the effects of siRNA-mediated inhibition of ALP that resulted in an impaired hBMSC differentiation not only to osteoblasts, but also to adipocytes. Also, our results corroborate earlier studies that demonstrated in human bone biopsies the presence of ALP expression in bone marrow adipocytic cells \[[@B13], [@B17]\]. All these data suggest that ALP is a "stemness" marker of hBMSC and not just an indicator of osteoblastic lineage commitment.

While CL1 and CL2 were isolated from telomerized hMSC cell line, they are relevant to normal human physiology. We observed that the molecular phenotypes of CL1 and CL2 were contained within the molecular signature of primary hBMSC suggesting that CL1 and CL2 represent cell populations within the heterogeneous cultures of hBMSC. We have also previously reported that the molecular phenotype and cellular responses of hMSC-TERT are similar to those of primary hMSC \[[@B10]\]. While we have identified ALP as a marker that can be used for a prospective identification of differentiation committed population of hBMSC, we identified additional distinctive molecular markers of the cells. For example, IGF-1, IGF-2, and IGF binding protein 5 were enriched in CL1 compared to CL2. IGFs and their binding proteins are very well-studied factors that play a role in hBMSC proliferation and osteoblast differentiation \[[@B18]\]. On the other hand, annexin A3 as well as several immune-related genes was highly enriched in CL2 compared to CL1. Future studies are needed to determine the functional significance of these molecules in relation to the functional identity of various cell populations within the hBMSC cultures and their usefulness as biomarkers to dissect the heterogeneous population of cultured hBMSC.

Our finding of the presence of functional diversity within hBMSC cultures that contain progenitor and nonprogenitor cell populations has a clinical relevance. It demonstrates that the progenitor function and the immune modulatory roles of hBMSC \[[@B42]\] are mediated by specific and distinguishable populations of hBMSC. Thus, future clinical studies employing hBMSC should attempt to administer the relevant subpopulation of hBMSC dependent on the experimental aim, as a novel approach to improving the clinical efficiency, instead of the current use of heterogeneous hBMSC populations.
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List of primers used for real time qPCR.
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![Cellular phenotype of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2. (a) Cell morphology. CL1 cells showed large cuboidal morphology while CL2 cells had spindle-shaped fibroblast-like morphology. (b) Growth curves showing population doubling (PD) rate during long term culture. (c) Flow cytometry analysis (FACS) shows expression of CD44, CD63, CD73, CD105, and CD166 in CL1 and CL2 cells. Matched isotype control was used for gating. (d) Flow cytometry analysis presented as dot blot of CD146 and alkaline phosphatase (ALP) cell surface proteins. (e) Transmission electron microscope (TEM). (A): CL1 (1200x); (B): CL2 (1500x). n: nucleus, nu: nucleolus, rER: rough endoplasmic reticulum, ly: lysosomes, pv: phagocytic vacuole, and rer: reticular stalk of rER. (f) Gene expression analysis using RT-PCR for a group of mesodermal and stromal genes. Gene expression was normalized to GAPDH and presented as fold change. Data is shown as mean ± SD of three independent experiments. ^*∗*^ *p* \< 0.05; ^\#^ *p* \< 0.001.](SCI2016-9378081.001){#fig1}

![*In vitro* osteoblastic and adipocytic differentiation of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2 cells. Both cell lines were induced for osteoblast differentiation using standard protocol described in the Methods. (a) ALP staining at day 14 in control noninduced (Cont) and osteoblast induced cells (D14). Right panel shows ALP activity (*n* = 3 independent experiments, ^\#^ *p* \< 0.001). (b) Mineralized matrix formation visualized by Alizarin Red S staining. Right panel shows Alizarin Red quantification at day 14 and 21 after osteoblast differentiation (*n* = 3 independent experiments, ^\#^ *p* \< 0.001). (c) Quantitative RT-PCR of osteoblastic and adipocyte gene markers in CL1 and CL2 during osteoblast (upper panel) and adipocyte (lower panel) differentiation. ALP = alkaline phosphatase, OPN = osteopontin, LPL = lipoprotein lipase, and ADIPOQ = adiponectin. Data are presented as fold change in expression of each target gene normalized to GAPDH (*n* = 3 independent experiments, *p* \< 0.05;  ^\#^ *p* \< 0.001). (d) CL1 and CL2 lines were induced for adipocyte differentiation using standard protocol described in the Methods. Adipocyte formation was visualized at day 7 (Adip d7) and day 14 (Adip d14) by Oil Red-O staining. Lower panel presents quantification of Nile red staining (*n* = 3 independent experiments, ^\#^ *p* \< 0.001). (e) CL1 and CL2 lines were induced for chondrocyte differentiation using 21-day pellet culture method as described in the Methods. The pellets were stained with Alcian blue, collagen 10 (Col X), and collagen 2 (Col II) (original magnification 5x).](SCI2016-9378081.002){#fig2}

![Validation of whole genome microarray analysis of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2 cells. Quantitative real-time PCR for highly expressed genes in CL1 cells. NOV = nephroblastoma overexpressed, IGFBP5 = insulin-like growth factor binding protein 5, ALP, TAGLN = transgelin, and CDH11 = OB-cadherin (osteoblast). Data are presented as fold change in expression of each target gene normalized to GAPDH (*n* = three independent experiments, ^\#^ *p* \< 0.001) (see also [Table 3](#tab3){ref-type="table"}).](SCI2016-9378081.003){#fig3}

![Effect of alkaline phosphatase (ALP) gene silencing by small interfering RNA (siRNA) on a clonal population of human bone marrow stromal stem cell CL1. (A) ALP staining at day 3, day 5, or day 7 days of osteoblast differentiation (OB induction). (B) Quantitative real-time PCR for ALP gene following ALP siRNA transfection at day 0 OB and day 7 of OB. Data are presented as fold change in expression of each target gene normalized to GAPDH (*n* = three independent experiments, ^\#^ *p* \< 0.01). Western blotting analysis of day 3 and day 7 after siRNA ALP transfection of CL1 cells, ALPL specific antibody, and B-actin was used. (C) Mineralized matrix formation as visualized by Alizarin Red S staining in siRNA transfected CL1 cells after 14 days of OB induction. (D) Nile red quantification of mature lipid filled adipocyte in control noninduced (Cont), adipocyte induced (Adip I), and ALP siRNA transfected cells that are adipocyte induced (ALP siRNA). Adipocyte induction was carried out for 7 days. ^*∗*^ *p* \< 0.05.](SCI2016-9378081.004){#fig4}

![Adipocyte related genes downregulated in ALP knockdown CL1 cells. (a) Venn diagram of whole gene expression analysis of AD upregulated genes compared with ALP KD downregulated genes. (b) Quantitative real-time PCR of four selected common genes from Venn diagram including ALPL, PPARg2, aP2, and LPL. Data are presented as fold change in expression of each target gene normalized to GAPDH (*n* = three independent experiments, ^*∗*^ *p* \< 0.05, ^*∗∗*^ *p* \< 0.01, and ^*∗∗∗*^ *p* \< 0.001).](SCI2016-9378081.005){#fig5}

###### 

Microarray data analysis showing genes related to bone development and osteoblast differentiation upregulated in CL1 versus CL2 cells.

  Probe ID        Genbank accession   Gene name                                                                                                           Gene symbol   FC
  --------------- ------------------- ------------------------------------------------------------------------------------------------------------------- ------------- --------
  A_23_P167367    NM_153426           Paired-like homeodomain 2                                                                                           PITX2         308.84
  A_23_P13907     NM_000618           Insulin-like growth factor 1 (somatomedin C)                                                                        IGF1          118.00
  A_23_P55749     NM_015719           Collagen, type V, alpha 3                                                                                           COL5A3        75.11
  A_23_P94397     NM_005014           Osteomodulin                                                                                                        OMD           56.07
  A_24_P128442    NM_152380           T-box 15                                                                                                            TBX15         54.38
  A_33_P3708413   NM_003480           Microfibrillar associated protein 5                                                                                 MFAP5         53.73
  A_24_P72064     NM_000163           Growth hormone receptor                                                                                             GHR           51.47
  A_23_P215454    NM_001278939        Elastin                                                                                                             ELN           50.15
  A_24_P200854    NM_006735           Homeobox A2                                                                                                         HOXA2         44.99
  A_23_P19624     NM_001718           Bone morphogenetic protein 6                                                                                        BMP6          41.43
  A_23_P500501    NM_000142           Fibroblast growth factor receptor 3                                                                                 FGFR3         33.95
  A_23_P154605    NM_018837           Sulfatase 2                                                                                                         SULF2         29.57
  A_23_P28815     NM_000782           Cytochrome P450, family 24, subfamily A, polypeptide 1                                                              CYP24A1       22.47
  A_23_P210109    NM_019885           Cytochrome P450, family 26, subfamily B, polypeptide 1                                                              CYP26B1       22.42
  A_23_P323180    NM_006898           Homeobox D3                                                                                                         HOXD3         21.08
  A_32_P405759    NM_152888           Collagen, type XXII, alpha 1                                                                                        COL22A1       20.36
  A_33_P3363799   NM_001242607        Neural cell adhesion molecule 1                                                                                     NCAM1         17.33
  A_33_P3381378   NM_001257096        Paired box 1                                                                                                        PAX1          17.12
  A_23_P383009    NM_000599           Insulin-like growth factor binding protein 5                                                                        IGFBP5        14.67
  A_33_P3382856   NM_133507           Decorin                                                                                                             DCN           14.38
  A_23_P10206     NM_005328           Hyaluronan synthase 2                                                                                               HAS2          14.33
  A_24_P77904     NM_018951           Homeobox A10                                                                                                        HOXA10        13.64
  A_23_P2814      NM_005905           SMAD family member 9                                                                                                SMAD9         12.45
  A_23_P88404     NM_003239           Transforming growth factor, beta 3                                                                                  TGFB3         12.11
  A_32_P4595      NM_000337           Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein)                                                      SGCD          8.95
  A_23_P162171    NM_006500           Melanoma cell adhesion molecule                                                                                     MCAM          8.60
  A_24_P38276     NM_003505           Frizzled class receptor 1                                                                                           FZD1          7.81
  A_23_P24129     NM_012242           Dickkopf WNT signaling pathway inhibitor 1                                                                          DKK1          7.04
  A_33_P3264528   NM_005523           Homeobox A11                                                                                                        HOXA11        6.64
  A_33_P3220470   NM_005585           SMAD family member 6                                                                                                SMAD6         6.47
  A_23_P23783     NM_000261           Myocilin, trabecular meshwork inducible glucocorticoid response                                                     MYOC          6.41
  A_33_P3263432   NM_003637           Integrin, alpha 10                                                                                                  ITGA10        6.35
  A_23_P383009    NM_000599           Insulin-like growth factor binding protein 5                                                                        IGFBP5        6.18
  A_33_P3219090   NM_005542           Insulin induced gene 1                                                                                              INSIG1        5.78
  A_23_P162589    NM_001017535        Vitamin D (1,25-dihydroxyvitamin D3) receptor                                                                       VDR           5.68
  A_23_P374695    NM_000459           TEK tyrosine kinase, endothelial                                                                                    TEK           5.65
  A_24_P261169    NM_006378           Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM), and short cytoplasmic domain, (semaphorin) 4D   SEMA4D        5.41
  A_33_P3297930   NM_005202           Collagen, type VIII, alpha 2                                                                                        COL8A2        5.138
  A_23_P206359    NM_004360           Cadherin 1, type 1, E-cadherin (epithelial)                                                                         CDH1          5.12
  A_24_P264943    NM_000095           Cartilage oligomeric matrix protein                                                                                 COMP          5.07
  A_33_P3214948   NM_014767           Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan (testican) 2                                           SPOCK2        4.54
  A_24_P55496     NM_053001           Odd-skipped related transcription factor 2                                                                          OSR2          4.38
  A_24_P354689    NM_004598           Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan (testican) 1                                           SPOCK1        4.23
  A_23_P69030     NM_001850           Collagen, type VIII, alpha 1                                                                                        COL8A1        3.93
  A_23_P128084    NM_002206           Integrin, alpha 7                                                                                                   ITGA7         3.91
  A_24_P3249      NM_000965           Retinoic acid receptor, beta                                                                                        RARB          3.91
  A_24_P168574    AJ224867            GNAS complex locus                                                                                                  GNAS          3.83
  A_23_P320739    NM_002397           Myocyte enhancer factor 2C                                                                                          MEF2C         3.74
  A_23_P429383    NM_014213           Homeobox D9                                                                                                         HOXD9         3.54
  A_23_P42322     NM_080680           Collagen, type XI, alpha 2                                                                                          COL11A2       3.42
  A_23_P160318    NM_001856           Collagen, type XVI, alpha 1                                                                                         COL16A1       3.36
  A_33_P3407013   NM_000600           Interleukin 6                                                                                                       IL6           3.30
  A_23_P315364    NM_002089           Chemokine (C-X-C motif) ligand 2                                                                                    CXCL2         3.29
  A_33_P3413168   BC007696            Collagen, type XXVII, alpha 1                                                                                       COL27A1       3.08
  A_23_P43164     NM_015170           Sulfatase 1                                                                                                         SULF1         3.05
  A_23_P58676     NM_001204375        Natriuretic peptide receptor 3                                                                                      NPR3          3.04
  A_33_P3290562   NM_000168           GLI family zinc finger 3                                                                                            GLI3          3.00
  A_23_P69497     NM_003278           C-type lectin domain family 3, member B                                                                             CLEC3B        2.99
  A_24_P353619    NM_000478           Alkaline phosphatase, liver/bone/kidney                                                                             ALPL          2.99
  A_33_P3305749   NM_000965           Retinoic acid receptor, beta                                                                                        RARB          2.89
  A_23_P307328    NM_007331           Wolf-Hirschhorn syndrome candidate 1                                                                                WHSC1         2.77
  A_23_P152305    NM_001797           Cadherin 11, type 2, OB-cadherin (osteoblast)                                                                       CDH11         2.77
  A_23_P216361    NM_021110           Collagen, type XIV, alpha 1                                                                                         COL14A1       2.62
  A_23_P7313      NM_001040058        Secreted phosphoprotein 1                                                                                           SPP1          2.60
  A_24_P267592    NM_015474           SAM domain and HD domain 1                                                                                          SAMHD1        2.54
  A_23_P210482    NM_000022           Adenosine deaminase                                                                                                 ADA           2.52
  A_23_P148047    NM_000958           Prostaglandin E receptor 4 (subtype EP4)                                                                            PTGER4        2.51
  A_23_P345725    NM_014621           Homeobox D4                                                                                                         HOXD4         2.47
  A_24_P125283    NM_001015053        Histone deacetylase 5                                                                                               HDAC5         2.37
  A_33_P3231953   NM_004370           Collagen, type XII, alpha 1                                                                                         COL12A1       2.34
  A_24_P298027    NM_004655           Axin 2                                                                                                              AXIN2         2.31
  A_24_P336551    NM_199173           Bone gamma-carboxyglutamate (gla) protein                                                                           BGLAP         2.29
  A_33_P3313825   XM_006713316        Transforming growth factor, beta receptor II (70/80 kDa)                                                            TGFBR2        2.23
  A_23_P82990     NM_033014           Osteoglycin                                                                                                         OGN           2.20
  A_32_P24585     NM_001017995        SH3 and PX domains 2B                                                                                               SH3PXD2B      2.20
  A_24_P944458    NM_016133           Insulin induced gene 2                                                                                              INSIG2        2.14
  A_23_P99063     NM_002345           Lumican                                                                                                             LUM           2.12
  A_32_P5251      NM_001024809        Retinoic acid receptor, alpha                                                                                       RARA          2.11
  A_24_P935491    NM_000090           Collagen, type III, alpha 1                                                                                         COL3A1        2.10
  A_33_P3312104   NM_025099           CTS telomere maintenance complex component 1                                                                        CTC1          2.06
  A_33_P3321342   NM_016133           Insulin induced gene 2                                                                                              INSIG2        2.04
  A_23_P100486    NM_206824           Vitamin K epoxide reductase complex, subunit 1                                                                      VKORC1        2.02
  A_23_P53588     NM_030775           Wingless-type MMTV integration site family, member 5B                                                               WNT5B         2.00
  A_23_P616356    NM_001291902        Low density lipoprotein receptor-related protein 5                                                                  LRP5          2.00

###### 

Microarray data analysis showing genes related immune modulation and immune defense genes upregulated in CL2 versus CL1 cells.

  ID               Gene name                                                                        Gene symbol   Fold change
  ---------------- -------------------------------------------------------------------------------- ------------- -------------
  A_23_P128094     ATP-binding cassette, subfamily B (MDR/TAP), member 9                            ABCB9         2.1
  A_32_P156963     Actin, gamma 1                                                                   ACTG1         3.0
  A_23_P28279      ARP1 actin related protein 1 homolog B, centractin beta (yeast)                  ACTR1B        2.0
  A_23_P211207     Adenosine deaminase, RNA-specific, B1                                            ADARB1        3.5
  A_23_P381261     Adenylate cyclase 4                                                              ADCY4         5.0
  A_23_P169993     Adenylate cyclase 8 (brain)                                                      ADCY8         3.2
  A_23_P76823      Adenylosuccinate synthase-like 1                                                 ADSSL1        7.0
  A_23_P135486     Alpha hemoglobin stabilizing protein                                             AHSP          2.6
  A_23_P216023     Angiopoietin 1                                                                   ANGPT1        7.6
  A_23_P94501      Annexin A1                                                                       ANXA1         2.6
  A_23_P121716     Annexin A3                                                                       ANXA3         346.8
  A_23_P6398       Adaptor-related protein complex 1, beta 1 subunit                                AP1B1         2.2
                                                                                                                  
  A_23_P120931     Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C              APOBEC3C      2.2
  A_23_P132316     Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D              APOBEC3D      2.4
  A_23_P357101     Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F              APOBEC3F      2.3
  A_23_P143713     Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G              APOBEC3G      9.6
                                                                                                                  
  A_23_P93988      Rho guanine nucleotide exchange factor (GEF) 5                                   ARHGEF5       8.7
  A_24_P20383      Actin related protein 2/3 complex, subunit 4, 20 kDa                             ARPC4         2.2
  A_23_P208389     AXL receptor tyrosine kinase                                                     AXL           2.0
  A_33_P3279353    Azurocidin 1                                                                     AZU1          4.8
  A_33_P3262043    BCL2-associated agonist of cell death                                            BAD           2.3
  A_24_P159648     BAI1-associated protein 2                                                        BAIAP2        2.2
                                                                                                                  
  A_23_P370682     Basic leucine zipper transcription factor, ATF-like 2                            BATF2         22.2
  A_23_P160720     Basic leucine zipper transcription factor, ATF-like 3                            BATF3         3.0
                                                                                                                  
  A_33_P3229272    Breast cancer antiestrogen resistance 1                                          BCAR1         3.3
  A_23_P210886     BCL2-like 1                                                                      BCL2L1        3.4
  A_23_P98350      Baculoviral IAP repeat containing 3                                              BIRC3         25.0
  A_23_P31725      B lymphoid tyrosine kinase                                                       BLK           7.3
  A_33_P3419785    BCL2/adenovirus E1B 19 kDa interacting protein 3                                 BNIP3         7.3
  A_19_P00802936   BRICK1, SCAR/WAVE actin-nucleating complex subunit                               BRK1          2.2
                                                                                                                  
  A_23_P2431       Complement component 3a receptor 1                                               C3AR1         2.6
  A_23_P97541      Complement component 4 binding protein, alpha                                    C4BPA         2.6
  A_23_P92928      Complement component 6                                                           C6            4.0
  A_23_P213857     Complement component 7                                                           C7            2.2
                                                                                                                  
  A_33_P3745146    Cell adhesion molecule 1                                                         CADM1         34.3
  A_23_P250347     Calcium/calmodulin-dependent protein kinase IV                                   CAMK4         3.4
  A_23_P253791     Cathelicidin antimicrobial peptide                                               CAMP          3.3
  A_23_P82324      Caspase recruitment domain family, member 11                                     CARD11        7.9
  A_23_P500433     Caspase recruitment domain family, member 9                                      CARD9         2.4
  A_23_P202978     Caspase 1, apoptosis-related cysteine peptidase                                  CASP1         2.4
                                                                                                                  
  A_23_P123853     Chemokine (C-C motif) ligand 19                                                  CCL19         2.0
  A_23_P17065      Chemokine (C-C motif) ligand 20                                                  CCL20         14.6
  A_23_P215484     Chemokine (C-C motif) ligand 26                                                  CCL26         2.8
  A_23_P503072     Chemokine (C-C motif) ligand 28                                                  CCL28         4.3
  A_33_P3316273    Chemokine (C-C motif) ligand 3                                                   CCL3          2.3
  A_23_P152838     Chemokine (C-C motif) ligand 5                                                   CCL5          2.7
  A_23_P78037      Chemokine (C-C motif) ligand 7                                                   CCL7          16.0
  A_23_P207456     Chemokine (C-C motif) ligand 8                                                   CCL8          2.8
                                                                                                                  
  A_23_P361773     Cyclin D3                                                                        CCND3         2.3
                                                                                                                  
  A_33_P3284508    CD14 molecule                                                                    CD14          4.2
  A_23_P259863     CD177 molecule                                                                   CD177         2.7
  A_33_P3381513    CD274 molecule                                                                   CD274         10.8
  A_23_P15369      CD300 molecule-like family member b                                              CD300LB       2.0
  A_23_P416747     CD3e molecule, epsilon (CD3-TCR complex)                                         CD3E          2.7
  A_24_P188377     CD55 molecule, decay accelerating factor for complement (Cromer blood group)     CD55          5.9
                                                                                                                  
  A_23_P300056     Cell division cycle 42                                                           CDC42         4.5
  A_32_P148710     Cofilin 1 (nonmuscle)                                                            CFL1          2.8
  A_33_P3217584    Cholinergic receptor, nicotinic, alpha 4 (neuronal)                              CHRNA4        2.9
  A_33_P3415300    Complexin 2                                                                      CPLX2         2.7
  A_23_P133408     Colony stimulating factor 2 (granulocyte-macrophage)                             CSF2          16.5
  A_33_P3396139    Cytotoxic T-lymphocyte-associated protein 4                                      CTLA4         3.0
  A_33_P3287631    Cathepsin B                                                                      CTSB          2.3
  A_33_P3283480    Cathepsin C                                                                      CTSC          8.2
  A_23_P7144       Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)   CXCL1         6.5
                                                                                                                  
  A_33_P3712341    Chemokine (C-X-C motif) ligand 12                                                CXCL12        4.8
  A_33_P3351249    Chemokine (C-X-C motif) ligand 16                                                CXCL16        11.6
  A_23_P315364     Chemokine (C-X-C motif) ligand 2                                                 CXCL2         3.3
  A_24_P183150     Chemokine (C-X-C motif) ligand 3                                                 CXCL3         2.9
  A_23_P155755     Chemokine (C-X-C motif) ligand 6                                                 CXCL6         5.0
  A_33_P3214550    Chemokine (C-X-C motif) receptor 2                                               CXCR2         2.0
  A_33_P3389230    Chemokine (C-X-C motif) receptor 3                                               CXCR3         2.3

###### 

Whole genome microarray analysis of two clonal populations of human bone marrow stromal stem cells: CL1 and CL2 cells. (a) Top 35 highly upregulated genes in CL1 cells versus CL2 cells. (b) Ingenuity® Pathway Analysis (IPA®) showing the different *physiological system development and function*genes found in each category and the corresponding *p* value. (c) Upper part IPA analysis showing the categories for *skeletal and muscular system development and function*upregulated in CL1 cells and lower part showing genes upregulated in CL2 cells. NOV = nephroblastoma overexpressed, IGFBP5 = insulin-like growth factor binding protein 5, ALP, TAGLN = transgelin, and CDH11 = OB-cadherin (osteoblast).

  ----------- ----------------------------
  Gene ID     Fold change CL1 versus CL2
              
  FOLR3       28.4721
  CCL3L3      17.936
  POSTN       15.5924
  SERPINB2    −17.2599
  IGFBP5      14.6708
  CCL3        13.1203
  NOV         11.2921
  ACTG2       10.4493
  CRYAB       10.0678
  PSG4        9.68913
  RAB3IL1     9.16897
  SCIN        9.13702
  MYL9        9.12814
  TNFRSF11B   8.86049
  TAGLN       8.75581
  CDH12       8.06682
  SHISA2      8.0291
  THBS1       7.86854
  SPP1        7.64205
  LCE2A       7.41042
  TMEM98      7.38011
  PSG7        7.12183
  MYPN        7.01837
  FNDC1       6.88102
  TNS3        6.72083
  ABI3BP      6.67822
  LRP3        6.64307
  MMP3        6.34715
  FAM167A     6.02684
  HSPB2       6.01063
  ALPL        6.01022
  CTSK        5.87356
  CXCL12      5.68572
  THY1        4.89445
  CDH10       4.86105
  ----------- ----------------------------

  Name                                                    *p* value                    \# molecules
  ------------------------------------------------------- ---------------------------- --------------
  Physiological system development and function                                        
  Organismal development                                  7.05*E* − 10--1.43*E* − 03   181
  Embryonic development                                   1.00*E* − 09--1.43*E* − 03   154
  Organ development                                       1.00*E* − 09--1.43*E* − 03   145
  Skeletal and muscular system development and function   1.00*E* − 09--1.02*E* − 03   123
  Tissue development                                      1.00*E* − 09--1.43*E* − 03   236

  Functions annotation                                                               *p* value      \# molecules
  ---------------------------------------------------------------------------------- -------------- --------------
   Skeletal and muscular system development and  function upregulated in CL1 cells                  
  Size of bone                                                                       1.43*E* − 06   24
  Differentiation of osteoblasts                                                     3.84*E* − 06   25
  Mineralization of bone                                                             4.93*E* − 06   19
  Bone mineral density                                                               3.65*E* − 05   19
                                                                                                    
   Skeletal and muscular system development and  function upregulated in CL2 cells                  
  Development of muscle                                                              1.00*E* − 09   44
  Proliferation of muscle cells                                                      2.29*E* − 06   35
  Remodeling of bone                                                                 3.63*E* − 06   21
  Resorption of bone                                                                 3.94*E* − 06   19

###### 

Microarray data analysis showing genes found to be upregulated during adipogenic differentiation and downregulated after ALP KO.

  62 common elements in "AD up" and "ALP down"   Gene name                                                                                 FC (ALP siRNA versus control siRNA)
  ---------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------
  APOBEC3G                                       Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G                       −15.938025
  IFI44L                                         Interferon-induced protein 44-like                                                        −11.520283
  PAQR5                                          Progestin and adipoQ receptor family member V                                             −6.868241
  PNMA2                                          Paraneoplastic antigen MA2                                                                −5.9695344
  DUSP23                                         Dual specificity phosphatase 23                                                           −5.4786854
  CLDN23                                         Claudin 23                                                                                −5.1885047
  ANKDD1A                                        Ankyrin repeat and death domain containing 1A                                             −5.1646647
  IL8                                            Interleukin 8                                                                             −4.887188
  LRRC23                                         Leucine rich repeat containing 23                                                         −4.7611775
  IL6                                            Interleukin 6 (interferon, beta 2)                                                        −4.693139
  LIFR                                           Leukemia inhibitory factor receptor alpha                                                 −4.6540866
  PTGFR                                          Prostaglandin F receptor (FP)                                                             −4.457529
  FAM134B                                        Family with sequence similarity 134, member B                                             −4.403495
  CYFIP2                                         Cytoplasmic FMR1 interacting protein 2                                                    −4.260462
  METTL7A                                        Methyltransferase-like 7A                                                                 −4.0480843
  APOBEC3F                                       Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F                       −3.9502614
  CA5B                                           Carbonic anhydrase VB, mitochondrial                                                      −3.93889
  ITGA10                                         Integrin, alpha 10                                                                        −3.9143775
  FMO3                                           Flavin containing monooxygenase 3                                                         −3.852087
  IMPA2                                          Inositol monophosphatase 2 (human)                                                        −3.8374884
  CDO1                                           Cysteine dioxygenase, type I                                                              −3.8181455
  CCDC68                                         Coiled-coil domain containing 68                                                          −3.7292893
  CXCL1                                          Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)            −3.5942702
  IDO1                                           Indoleamine 2,3-dioxygenase 1                                                             −3.5803545
  KCNIP3                                         Kv channel interacting protein 3, calsenilin                                              −3.5442894
  FADS1                                          Fatty acid desaturase 1                                                                   −3.2951858
  LSR                                            Lipolysis stimulated lipoprotein receptor                                                 −3.2215986
  ITGA7                                          Integrin, alpha 7                                                                         −3.1355932
  HLA-DMA                                        Major histocompatibility complex, class II, DM alpha                                      −3.1347752
  APOBEC3B                                       Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B                       −3.1074922
  BMP4                                           Bone morphogenetic protein 4                                                              −3.0809238
  DMBT1                                          Deleted in malignant brain tumors 1                                                       −3.0760298
  RDH5                                           Retinol dehydrogenase 5 (11-cis/9-cis)                                                    −3.066812
  EPAS1                                          Endothelial PAS domain protein 1                                                          −3.0615559
  CDKN3                                          Cyclin-dependent kinase inhibitor 3                                                       −3.052319
  GPC6                                           Glypican 6                                                                                −3.0460389
  CDK4                                           Cyclin-dependent kinase 4                                                                 −2.9808035
  FKBP5                                          FK506 binding protein 5                                                                   −2.9360793
  PDE1B                                          Phosphodiesterase 1B, calmodulin-dependent                                                −2.8863106
  JAM2                                           Junctional adhesion molecule 2                                                            −2.884354
  TFPI                                           Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)            −2.8578906
  NT5M                                           5′,3′-Nucleotidase, mitochondrial                                                         −2.7555947
  NFIA                                           Nuclear factor I/A                                                                        −2.7176137
  TSPAN31                                        Tetraspanin 31                                                                            −2.627556
  ZNF25                                          Zinc finger protein 25                                                                    −2.6183622
  SULF2                                          Sulfatase 2                                                                               −2.5464642
  MESP1                                          Mesoderm posterior 1 homolog (mouse)                                                      −2.525513
  BCL2L1                                         BCL2-like 1                                                                               −2.5119667
  PLTP                                           Phospholipid transfer protein                                                             −2.4767148
  TIMP4                                          TIMP metallopeptidase inhibitor 4                                                         −2.465897
  CYP27A1                                        Cytochrome P450, family 27, subfamily A, polypeptide 1                                    −2.4572072
  TTC39B                                         Tetratricopeptide repeat domain 39B                                                       −2.4439611
  IL1R2                                          Interleukin 1 receptor, type II                                                           −2.427431
  FMOD                                           Fibromodulin                                                                              −2.4185398
  LDLRAD3                                        Low density lipoprotein receptor class A domain containing 3                              −2.4032724
  PISD                                           Phosphatidylserine decarboxylase                                                          −2.3884957
  TMEM100                                        Transmembrane protein 100                                                                 −2.384632
  CHST2                                          Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2                                 −2.3805838
  APOBEC3F                                       Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F                       −2.3759322
  SCD                                            Stearoyl-CoA desaturase (delta-9-desaturase)                                              −2.3524246
  SPAG4                                          Sperm associated antigen 4                                                                −2.280867
  MMD                                            Monocyte to macrophage differentiation associated human                                   −2.2055967
  ASS1                                           Argininosuccinate synthase 1                                                              −2.1725202
  GK5                                            Glycerol kinase 5 (putative)                                                              −2.1667244
  PDE7B                                          Phosphodiesterase 7B                                                                      −2.166515
  MT1X                                           Metallothionein 1X                                                                        −2.161843
  ACACB                                          Acetyl-CoA carboxylase beta                                                               −2.1512873
  LEPR                                           Leptin receptor                                                                           −2.148686
  HIF1A                                          Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)   −2.0954225
  HEXDC                                          Hexosaminidase (glycosyl hydrolase family 20, catalytic domain) containing                −2.094836
  SARM1                                          Sterile alpha and TIR motif containing 1                                                  −2.0797038
  BBS1                                           Bardet-Biedl syndrome 1                                                                   −2.0146718
  SERPING1                                       Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1                              −2.0102212
  FAM162A                                        Family with sequence similarity 162, member A                                             −2.005807
  TCTN1                                          Tectonic family member 1                                                                  −2.0033443

[^1]: Academic Editor: Giorgio Mori
